REG - Ovoca Bio PLC - Notice of AGM

Ovoca BioAnnouncement

06/10/2022 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221006:nRSF0665Ca&default-theme=true

RNS Number : 0665C  Ovoca Bio PLC  06 October 2022

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

 

Notice of AGM

 

Dublin, Ireland, October 6, 2022 - Ovoca Bio, a biopharmaceutical company with
a focus on women's health, announces that a Notice of Annual General Meeting
("AGM"), containing details of the resolutions to be proposed at the AGM, has
been published and posted to shareholders. The Notice of AGM is also available
on the Company's website at www.ovocabio.com (http://www.ovocabio.com) .

 

The Company's 2022 AGM will be held via live conference facility on 27 October
2022 at 4 p.m. Further details in relation to shareholder participation in the
meeting is detailed in the Notice of AGM. The Company acknowledges that many
shareholders may not be in a position to physically attend the meeting in
person and as such has decided to hold this year's AGM entirely
electronically, in accordance with the provisions of section 6 of the
Companies (Miscellaneous Provisions) (Covid-19) Act 2020 and has put in place
a number of measures to facilitate remote participation by all shareholders,
as further explained in the Notice of AGM.

 

It will be possible to fully participate in the meeting using the live
conferencing facility provided by the Company for this purpose. Shareholders
will be able to use this facility to vote and /or ask questions. Shareholders
will also be able to submit questions in advance of the AGM in writing by
email to the Company Secretary at info@ovocabio.com to be received no later
than 4 p.m. on 25 October 2022. All correspondence should include sufficient
information to identify the shareholder on the Register of Members. Questions
submitted using these methods will be addressed by the Chairman at the AGM,
where possible.

 

 

End

 

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

 

 

 

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on
women's health. The Company is currently developing a novel treatment for
women with hypoactive sexual desire disorder (HSDD), a condition characterized
by a distressing lack or loss of sexual desire affecting an estimated ~4
million premenopausal women in the US alone.

 

The Company's lead product, Orenetide (BP-101), a novel synthetic peptide
administered through a nasal spray, is clinically validated, with Phase II and
Phase III studies conducted in Russia demonstrating statistically significant
improvement in a number of key efficacy outcomes, including an increase in
female sexual desire and reduction of symptoms of distress associated with
HSDD.

 

Ovoca Bio has been granted marketing approval in the Russian Federation and is
seeking to develop the drug for major global markets - in particular the
United States and Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABDBDGSUGDGDL